Hair loss is an issue often associated with men but 40 percent of women says they experience it by age 40 so dermatologist Dr ...

Prostate health is a significant concern for many men, particularly as they age. Problems such as frequent urination, ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

New research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

As Michael Urie prepares to get back to work on Shrinking, it will be a bittersweet return to set. The first-time Critics’ Choice Award winner opened up to Deadline at Friday’s awards show ...